Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous MK-3475A versus intravenous pembrolizumab in first-line metastatic PD-L1-high non-small cell lung cancer
ChiCTR2400092825Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and hyaluronidase in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Cycle 1 AUC0-6 weeks and Cycle 3 trough concentration. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
pembrolizumabhyaluronidase
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400092825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092825.